172 related articles for article (PubMed ID: 34609986)
1. Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Potential for Improved Primary Prevention With Statins.
Ballarano CA; Frishman WH
Cardiol Rev; 2021 Nov-Dec 01; 29(6):323-327. PubMed ID: 34609986
[TBL] [Abstract][Full Text] [Related]
2. Statins for prevention of cardiovascular disease in systemic lupus erythematosus.
Yousef Yengej FA; Limper M; Leavis HL
Neth J Med; 2017 Apr; 75(3):99-105. PubMed ID: 28469051
[TBL] [Abstract][Full Text] [Related]
3. Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention.
Reiss AB; Jacob B; Ahmed S; Carsons SE; DeLeon J
Inflammation; 2021 Oct; 44(5):1663-1682. PubMed ID: 33821395
[TBL] [Abstract][Full Text] [Related]
4. Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus.
Artola RT; Mihos CG; Santana O
South Med J; 2016 Nov; 109(11):705-711. PubMed ID: 27812716
[TBL] [Abstract][Full Text] [Related]
5. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
Yu HH; Chen PC; Yang YH; Wang LC; Lee JH; Lin YT; Chiang BL
Atherosclerosis; 2015 Nov; 243(1):11-8. PubMed ID: 26342937
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies.
Masson W; Rossi E; Mora-Crespo LM; Cornejo-Peña G; Pessio C; Gago M; Alvarado RN; Scolnik M
Clin Rheumatol; 2020 Feb; 39(2):455-462. PubMed ID: 31802350
[TBL] [Abstract][Full Text] [Related]
7. Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy.
Reiss AB; Arain HA; Kasselman LJ; Renna HA; Zhen J; Voloshyna I; DeLeon J; Carsons SE; Petri M
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31438615
[No Abstract] [Full Text] [Related]
8. Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review.
Fasano S; Margiotta DP; Navarini L; Pierro L; Pantano I; Riccardi A; Afeltra A; Valentini G
Lupus; 2017 Dec; 26(14):1463-1472. PubMed ID: 28786768
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Impact of Statins on the Lipid Profile and Cardiovascular Risk in Patients With Systemic Lupus Erythematosus: Systematic Review of the Literature and a Meta-analysis.
Sánchez P; Toro-Trujillo E; Muñoz-Velandia OM; García AA; Fernández-Ávila DG
Reumatol Clin (Engl Ed); 2019; 15(6):e86-e91. PubMed ID: 29428197
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment.
Ruiz-Limon P; Barbarroja N; Perez-Sanchez C; Aguirre MA; Bertolaccini ML; Khamashta MA; Rodriguez-Ariza A; Almadén Y; Segui P; Khraiwesh H; Gonzalez-Reyes JA; Villalba JM; Collantes-Estevez E; Cuadrado MJ; Lopez-Pedrera C
Ann Rheum Dis; 2015 Jul; 74(7):1450-8. PubMed ID: 24658835
[TBL] [Abstract][Full Text] [Related]
11. [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].
Sarzi-Puttini P; Atzeni F; Carrabba M
Minerva Med; 2003 Apr; 94(2):63-70. PubMed ID: 12858154
[TBL] [Abstract][Full Text] [Related]
12. [Assessing the cardiovascular risk in patients with systemic lupus erythematosus].
Arnaud L; Mathian A; Bruckert E; Amoura Z
Rev Med Interne; 2014 Nov; 35(11):723-9. PubMed ID: 25234464
[TBL] [Abstract][Full Text] [Related]
13. Do all lupus patients need statins?
Soubrier M; Mathieu S; Hermet M; Makarawiez C; Bruckert E
Joint Bone Spine; 2013 May; 80(3):244-9. PubMed ID: 23098926
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients.
Yang L; Tao J; Tang X; Wang Y; He X; Xu G; Ren Y; Tu Y
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):95-101. PubMed ID: 21851424
[TBL] [Abstract][Full Text] [Related]
15. Systemic lupus erythematosus and cardiovascular disease.
Frostegård J
Lupus; 2008 May; 17(5):364-7. PubMed ID: 18490408
[TBL] [Abstract][Full Text] [Related]
16. Systemic lupus erythematosus and cardiovascular disease.
Frostegård J
J Intern Med; 2023 Jan; 293(1):48-62. PubMed ID: 35982610
[TBL] [Abstract][Full Text] [Related]
17. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies.
Watanabe T; Oku K; Amengual O; Hisada R; Ohmura K; Nakagawa I; Shida H; Bohgaki T; Horita T; Yasuda S; Atsumi T
Lupus; 2018 Feb; 27(2):225-234. PubMed ID: 28659045
[TBL] [Abstract][Full Text] [Related]
18. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
19. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials.
Sahebkar A; Rathouska J; Derosa G; Maffioli P; Nachtigal P
Autoimmun Rev; 2016 Apr; 15(4):344-53. PubMed ID: 26747436
[TBL] [Abstract][Full Text] [Related]
20. Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells.
Tu H; Li Q; Xiang S; Jiang H; Mao Y; Shou Z; Chen J
Atherosclerosis; 2012 May; 222(1):29-33. PubMed ID: 22417842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
